Trial
NCT03999515
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Janssen Research & Development, LLC
Condition
Castration-Resistant Prostate Carcinoma
Intervention
Abiraterone Acetate
Why stopped
Terminated due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-28